INmune Bio, Inc.
INMBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 22, 2024 | Scotiabank | George Farmer | $22.00(+221%) | $6.85 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| LUCID CAPITAL MARKETS | upgrade | Neutral →Buy | Mar 11, 2026 |
| Maxim Group | maintain | Buy | Jul 2, 2025 |
| Scotiabank | downgrade | Sector Outperform →Sector Underperform | Jul 1, 2025 |
| BTIG | downgrade | Buy →Neutral | Jul 1, 2025 |
| Maxim Group | maintain | Buy | Feb 13, 2025 |
| Scotiabank | maintain | Sector Outperform | Feb 11, 2025 |
| Baird | maintain | Outperform | Jun 1, 2023 |
| B. Riley Securities | downgrade | Buy →Neutral | May 24, 2022 |
| BTIG | maintain | Buy | May 24, 2022 |
| B. Riley Securities | maintain | Buy | Jan 24, 2022 |
| B. Riley Securities | maintain | Buy | Apr 21, 2021 |
| B. Riley FBR | maintain | Buy | Apr 21, 2021 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2020 |
| H.C. Wainwright | maintain | Buy | Nov 25, 2020 |
| BTIG | maintain | Buy | Nov 25, 2020 |
| HC Wainwright & Co. | maintain | Buy | Nov 9, 2020 |
| BTIG | maintain | Buy | Sep 1, 2020 |
| HC Wainwright & Co. | maintain | Buy | Jul 15, 2020 |
| H.C. Wainwright | maintain | Buy | May 15, 2020 |
| H.C. Wainwright | maintain | Buy | Mar 12, 2020 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2020 |
| Maxim Group | maintain | Buy | Mar 19, 2019 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.19| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.17 | $-0.15 | — | $1.9M |
| Aug 6, 2026 | $-0.05 | $-0.21 | — | $1.2M |
| May 7, 2026 | $-0.20 | $-0.24 | — | $1.1M |
| Mar 30, 2026 | $-0.18 | $-0.27 | — | -$6.1K |
| Oct 30, 2025 | $-0.24 | $-0.31 | — | — |
| Aug 7, 2025 | $-1.05 | $-0.37 | — | $3.0K |
| May 8, 2025 | $-0.43 | $-0.43 | $50.0K | — |
| Mar 27, 2025 | $-0.40 | $-0.54 | — | — |
News
INmune Bio Inc. ( INMB ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Daniel Carlson - Head of Investor Relations David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Alex Hersham Presentation Operator Greetings, and welcome to INmune Bio's 2026 Third Quarter Earnings Call. As a reminder…
Company Advances Ebstrocel™ Toward Potential UK Approval Company to Host Conference Call on November 5, 2026, at 4:30pm ET BOCA RATON, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the quarter ended September 30, 2026, and provides a business update.
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5th, 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event,…
BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares common stock (together, …
BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has updated its regul…
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international a…
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development BOCA RATON, Fla. and HOBOKEN, N.J.
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.
The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity